In conclusion, in this study, using CADD-based small molecule inhibitors of SGK1 as pharmacological probes to complement genetic inhibition of SGK1, we have demonstrated ‘proof-of-concept’ SGK1 inhibition as a therapeutic target for ventricular arrhythmias. Here, SGK1 is linked to Ventricular arrhythmia.